Medicenna will present updated data related to MDNA55 at the Glioblastoma Development Summit in Boston in February 2026. ABILITY-1 clinical data for MDNA11 shows promising activity. MDNA11 demonstrated an ORR of 36% in the monotherapy setting and 43% when combined with pembrolizumab in certain expansion cohorts. Medicenna is also evaluating MDNA11 in combination with nivolumab for melanoma in the NEO-CYT study. MDNA113, a bifunctional anti-PD-1-IL-2 superkine, is advancing toward IND submission. Updated cash guidance provides runway into Q3 2026. Medicenna also announced changes to its Board of Directors.

Read more at GlobeNewswire: Medicenna Therapeutics Reports Third Quarter Fiscal 2026